FROM PATHOGENESIS TO THERAPEUTICS: TARGETING TWO SIGNALLING PATHWAYS AS A THERAPEUTIC STRATEGY TO TREAT PREECLAMPSIA
Grant number: 1126710 | Funding period: 2017 - 2020
Preeclampsia is a serious complication of pregnancy that claims the lives of thousands of mothers and babies each year. There is no efficacious medical treatment besides delivery of the baby and placenta. Our lack of therapeutics is largely a result of our poor understanding of the disease. In this application we plan to thoroughly characterise two pathways we believe responsible for preeclampsia, effectively identifying many points at which new therapies could be targeted.
Related publications (1)
Placental growth factor is negatively regulated by epidermal growth factor receptor (EGFR) signaling.
Carole-Anne Whigham, Roxanne Hastie, Natalie J Hannan, Fiona Brownfoot, Natasha Pritchard, Ping Cannon, Tuong Vi Nguyen, Manju Kandel, Joshua Masci, Stephen Tong, Tu'uhevaha J Kaitu'u-Lino
INTRODUCTION: Preeclampsia is associated with reduced pro-angiogenic Placental Growth Factor (PlGF) and increased levels of anti-a..